Search Patents
  • Fatty Acid Complexes Of Coronavirus Spike Protein And Their Use
    Publication number: 20230227506
    Abstract: Complexes of coronavirus spike proteins, as well as fragments or mutants thereof wherein the fragment or mutant thereof at least contains a receptor binding domain of said coronavirus spike protein, with linoleic acid, or a derivative or a salt or a mimetic thereof. Methods for producing the complexes of the invention by incubating coronavirus spike proteins with linoleic acid or a derivative or a salt or a mimetic thereof. . In vitro methods for identifying molecules which have therapeutic potential for diseases caused by coronaviruses by contacting the molecule with a coronavirus spike protein and linoleic acid or a derivative or salt or mimetic thereof. A method of treatment of coronavirus infection by administration of linoleic acid, or a derivative, a salt or a mimetic thereof to a subject in need thereof, by administration of an aerosol formulation or dry powder formulation to the respiratory tract, preferably by nasal administration.
    Type: Application
    Filed: June 18, 2021
    Publication date: July 20, 2023
    Inventors: Daniel Joseph Fitzgerald, Imre Berger, Christiane Berger-Schaffitzel, Christine Toelzer, Kapil Gupta
  • MODIFIED S2 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN
    Publication number: 20220213148
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 865. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Application
    Filed: May 6, 2020
    Publication date: July 7, 2022
    Inventors: Annika KRAEMER-KUEHL, Thomas Min Stephan
  • MODIFIED S1 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN
    Publication number: 20200354410
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Application
    Filed: May 6, 2020
    Publication date: November 12, 2020
    Inventors: Annika KRAEMER-KUEHL, Thomas Min STEPHAN, Hans-Christian PHILIPP
  • Modified S1 subunit of the coronavirus spike protein
    Patent number: 11512115
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: November 29, 2022
    Inventors: Annika Kraemer-Kuehl, Thomas Min Stephan, Hans-Christian Philipp
  • MODIFIED S1 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN
    Publication number: 20230340028
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Application
    Filed: November 28, 2022
    Publication date: October 26, 2023
    Applicant: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Annika KRAEMER-KUEHL, Thomas Min STEPHAN, Hans-Christian PHILIPP
  • Modified S1 subunit of the coronavirus spike protein
    Patent number: 11964999
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Grant
    Filed: November 28, 2022
    Date of Patent: April 23, 2024
    Assignee: Boehringer Ingelheim Vetmedia GmbH
    Inventors: Annika Kraemer-Kuehl, Thomas Min Stephan, Hans-Christian Philipp
  • METHODS AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS SPIKE PROTEINS
    Publication number: 20170096455
    Abstract: The present invention provides compositions and methods comprising a chimeric coronavirus spike protein.
    Type: Application
    Filed: March 20, 2015
    Publication date: April 6, 2017
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: Ralph Baric, Sudhakar Agnihothram, Boyd Yount
  • Methods and compositions for chimeric coronavirus spike proteins
    Patent number: 9884895
    Abstract: The present invention provides compositions and methods comprising a chimeric coronavirus spike protein.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: February 6, 2018
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Ralph Baric, Sudhakar Agnihothram, Boyd Yount
  • NANOBODIES DIRECTED TO CORONAVIRUS SPIKE PROTEIN RECEPTOR BINDING DOMAIN AND USES THEREOF
    Publication number: 20230235027
    Abstract: The invention generally relates to VHH domains that specifically bind a severe acute respiratory syndrome coronavirus spike protein receptor binding domain, corresponding expression vectors and host cells, and methods of treatment using such VHH domains.
    Type: Application
    Filed: July 23, 2021
    Publication date: July 27, 2023
    Inventors: David Brody, Thomas J. Esparza
  • HUMAN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AGAINST CORONAVIRUS SPIKE PROTEIN
    Publication number: 20230312689
    Abstract: It is an object of the present invention to provide antibodies against coronavirus (SARS-CoV-2). It is also an object of the present invention to provide a pharmaceutical composition against coronavirus infection using the antibody. According to the present invention, an antibody or antigen-binding fragment thereof that binds to the receptor-binding domain present in the spike protein of coronavirus and is capable of neutralizing the coronavirus, and a pharmaceutical composition for the prevention or treatment of coronavirus infection containing the antibody or antigen-binding fragment, are provided.
    Type: Application
    Filed: July 9, 2021
    Publication date: October 5, 2023
    Applicants: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, The University of Tokyo
    Inventors: Shuzo MATSUSHITA, Yu KAKU, Takeo KUWATA, Yoshihiro KAWAOKA, Masaki IMAI, Seiya YAMAYOSHI
  • DNA encoding the Canine coronavirus spike protein
    Patent number: 5661006
    Abstract: The invention is related to a nucleic acid sequence &coding a Canine coronavirus (CCV) spike protein. Such a protein can be used for the immunization of dogs against CCV infection. The nucleic acid sequence encoding the CCV spike protein can be applied for the preparation of the spike protein by means of genetic engineering techniques or can be applied for the preparation of vector vaccines.
    Type: Grant
    Filed: September 19, 1994
    Date of Patent: August 26, 1997
    Assignee: Akzo Nobel N.V.
    Inventors: Thomas David Kay Brown, Brian Colin Horsburgh
  • RECOMBINANT VECTORS ENCODING CHIMERIC CORONAVIRUS SPIKE PROTEINS AND USE THEREOF
    Publication number: 20240000920
    Abstract: The present invention provides recombinant vectors encoding a chimeric coronavirus spike protein. The present invention further provides new immunogenic compositions and vaccines comprising these recombinant vectors. Methods of administering these immunogenic compositions and vaccines to animal subjects, including humans, felines, and avians, to protect them against coronaviruses also are included. Methods of making the immunogenic compositions and vaccines alone or in combinations with other protective agents are provided too.
    Type: Application
    Filed: November 11, 2021
    Publication date: January 4, 2024
    Applicant: Intervet Inc.
    Inventors: Martijn Alexander Langereis, Ad De Groof, Paul Vermeij, Berend Jan Bosch
  • Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
    Publication number: 20170340728
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome—Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Application
    Filed: June 26, 2017
    Publication date: November 30, 2017
    Inventors: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam
  • Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
    Publication number: 20150337029
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Application
    Filed: May 20, 2015
    Publication date: November 26, 2015
    Inventors: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam
  • Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
    Publication number: 20190351049
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome—Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Application
    Filed: August 2, 2019
    Publication date: November 21, 2019
    Inventors: Christos KYRATSOUS, Neil STAHL, Sumathi SIVAPALASINGAM
  • SARS CORONAVIRUS 2 DIAGNOSTIC KIT INCLUDING RECEPTOR AND ANTIBODY BINDING TO SARS CORONAVIRUS 2 SPIKE PROTEIN
    Publication number: 20230160895
    Abstract: Provided are a composition for detecting SARS coronavirus 2, a composition for diagnosing SARS coronavirus 2 infection, a method for detecting SARS coronavirus 2, and a SARS coronavirus 2 infection diagnostic kit, wherein a receptor and an antibody that binds to SARS coronavirus 2 spike protein are used in order to detect SARS coronavirus 2 (SARS-CoV-2) or diagnose SARS coronavirus 2 infection (COVID-19).
    Type: Application
    Filed: June 18, 2021
    Publication date: May 25, 2023
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Hong Gi KIM, Jonghwan LEE, Bum Tae KIM
  • Coronavirus Spike Protein-Specific Antibody and Use Thereof
    Publication number: 20230417748
    Abstract: Provided are a coronavirus spike (S) protein-specific antibody and use thereof.
    Type: Application
    Filed: November 5, 2021
    Publication date: December 28, 2023
    Inventors: Dong-Sik KIM, Sua LEE, Shin A JANG, Jihoon KANG, KI Joon CHO, Soo Bin PARK, Young Woo HAN, Hyemi NAM, Mi Young OH, Jee Boong LEE, Jihye RYU, Mun Kyung KIM, Jeewon LEE
  • HAPTENIZED CORONAVIRUS SPIKE PROTEINS
    Publication number: 20230149534
    Abstract: The disclosure provides an immunogenic composition comprising an haptenized Spike protein (S protein) or fragment thereof from a coronavirus and at least one pharmaceutically acceptable carrier, wherein the coronavirus comprising severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Further disclosed are methods of using the haptenized S proteins from coronavirus or immunizing a subject against coronavirus infection.
    Type: Application
    Filed: March 19, 2021
    Publication date: May 18, 2023
    Inventors: David Berd, James Passin
  • NOVEL CORONAVIRUS RECOMBINANT SPIKE PROTEIN, POLYNUCLEOTIDE ENCODING SAME, VECTOR COMPRISING POLYNUCLEOTIDE, AND VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION, COMPRISING VECTOR
    Publication number: 20230293670
    Abstract: The present invention relates to a novel coronavirus recombinant spike protein, a polynucleotide encoding the same, a vector comprising the polynucleotide, and a vaccine for preventing or treating coronavirus infection, comprising the vector. The coronavirus recombinant spike protein of the present invention is stable and thereby not easily decomposed in cells, and effectively activates immune cells thereby resulting in a high antibody production amount and T cell reactivity. It was confirmed that the vector of the present invention exhibits a high antigen expression level and thereby has a high antibody production amount and T cell reactivity, has a long antibody production period and expression period, and does not show liver toxicity. Accordingly, the vector of the present invention can be helpfully used as a vaccine for preventing or treating coronavirus infection.
    Type: Application
    Filed: August 27, 2021
    Publication date: September 21, 2023
    Inventors: Chang-Yuil KANG, Seung-Phil SHIN, Kwang-Soo SHIN, Tae-Gwon OH
  • SINGLE DOMAIN ANTIBODIES TARGETING SARS CORONAVIRUS SPIKE PROTEIN AND USES THEREOF
    Publication number: 20230391852
    Abstract: Polypeptides that specifically bind the spike (S) protein of human coronavirus, selected from six camel VHH single domain antibody phage display libraries, are described. The S protein-specific polypeptides disrupt binding of the SARS-CoV-2 and/or SARS-CoV S protein to the cellular receptor ACE2, which is important for neutralization of the virus. Use of the S protein-specific polypeptides for the diagnosis and treatment of SARS-CoV-2 and/or SARS-CoV is described.
    Type: Application
    Filed: October 26, 2021
    Publication date: December 7, 2023
    Applicant: The U.S.A., as Represented by the Secretary, Department of Health and Human Services
    Inventors: Mitchell Ho, Jessica Diana Hong
Narrow Results

Filter by US Classification